Showing 3591-3600 of 8741 results for "".
- Nu Skin Launches ageLOC LumiSpa iOhttps://practicaldermatology.com/news/nu-skin-launches-ageloc-lumispa-io/2461437/Nu Skin Enterprises is introducing ageLOC LumiSpa iO system, a smart skin treatment and cleansing device with a connected, immersive experience. Featuring Nu Skin's patented micropulse technology, the new ageLOC LumiSpa iO system offers customized treatment options, intel
- Merz Aesthetics Now Offering the SaltFacial by SaltMEDhttps://practicaldermatology.com/news/merz-aesthetics-now-offering-the-saltfacial-by-saltmed/2461433/Merz Aesthetics and SaltMED are extending their commercial agreement adding The SaltFacial by SaltMED to the portfolio of products offered by Merz Aesthetics. The SaltFacial is a skin rejuvenation system that targets the texture, tone ,and color of skin.
- AD News: Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapyhttps://practicaldermatology.com/news/ad-news-alphyn-biologics-completes-first-cohort-of-phase2a-clinical-trial-of-topical-therapy-1/2461432/Alphyn Biologics completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mil
- Supergoop! Founder & CEO Named Ernst & Young LLP’s Entrepreneurs of the Year for 2022https://practicaldermatology.com/news/supergoop-founder-ceo-named-ernst-young-llps-entrepreneurs-of-the-year-for-2022/2461430/Holly Thaggard and Amanda Baldwin of Supergoop! are Ernst & Young LLP’s Entrepreneurs of the Year for 2022. The Entrepreneur of the Year program honors and elevates entrepreneurs who think big and act boldly to change our world for nearly four decades.
- NEA's Eczemawise Wins Two Top Prizes from eHealthcare Leadership Awardshttps://practicaldermatology.com/news/neas-eczemawise-wins-two-top-prizes-from-ehealthcare-leadership-awards/2461424/The
- Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in PsA, Non-Radiographic Axial Spondyloarthritis, and AShttps://practicaldermatology.com/news/bimekizumab-demonstrated-sustained-clinical-responses-to-week-52-in-phase-3-studies-in-psa-non-radiographic-axial-spondyloarthritis-and-as/2461422/Bimekizumab demonstrated sustained clinical responses to Week 52 in Phase 3 studies in psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.. The findings were presented at the ACR Convergence 2022 in Philadelphia, November 10–14, 2022. <
- Cutera's AviClear Now Broadly Available to US Physicians and Practitionershttps://practicaldermatology.com/news/cuteras-aviclear-now-broadly-available-to-us-physicians-and-practitioners/2461416/Cutera, Inc.’s AviClear is now broadly available to physicians and practitioners treating patients throughout North America. AviClear is the first and only energy device to be both U.S. Food and Drug Administration cleared and Health Canada approved for
- Updated: USPS Task Force Says More Research Needed to Recommend Screening Adolescents and Adults without Skin Cancer Symptomshttps://practicaldermatology.com/news/usps-task-force-more-research-needed-to-recommend-screening-adolescents-and-adults-without-skin-cancer-symptoms/2461415/More research is needed to recommend for or against screening adolescents and adults without skin cancer symptoms, according to the U.S. Preventive Services Task Force. The Task Force determined that there is not enough evidence to recommend for or against screening people without
- Hydrafacial and Glytone Team Up to Launch New Boosterhttps://practicaldermatology.com/news/hydrafacial-and-glytone-team-up-to-launch-new-booster/2461414/The Beauty Health Company’s Hydrafacial is rolling out a new exfoliating booster co-created with Glytone. The Glytone AHA Resurfacing Cellular Booster leverages a unique combination of three alpha hydroxy acids (AHAs) that may help improve the appearance of skin surface and textur
- November is Hyperhidrosis Awareness Monthhttps://practicaldermatology.com/news/november-is-hyperhidrosis-awareness-month-1/2461411/November is Hyperhidrosis Awareness Month and the